This is an update of a Cochrane
Tumor necrosis factor inhibitors are the favored therapeutic agents for the treatment of ankylosing spondylitis
Objective
Results Both pharmacological and non‐pharmacological interventions considered to be of interest to clinicians involved in the management of AS were
Self care
Expert opinion from Rajesh Mishra MBBS · Less than a year of experience · India Other areas of the body affected by ankylosing spondylitis include the eyes, heart, and
Discontinuation of sulphasalazine led to complete resolution of tinnitus and an improvement in hearing loss
Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (review)
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion
, 14 SSZ was found to be ineffective in patients with ankylosing spondylitis when compared to TNF inhibitors, especially in patients with predominant axial disease Am Fam Physician
Advanced Search Objective To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA)
The effectiveness of sulfasalazine in AS still lacks strong evidence, as well, the magnitude of its benefit is unknown
Cochrane Database Syst Rev 2014; 11: CD004800
Based on new evidence and an expert consensus, the American College of Rheumatology (ACR), the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network released updated recommendations for the treatment of axial spondyloarthritis (SpA), which comprises ankylosing spondylitis (AS) and
Methods
d
A Cochrane review showed that there is not enough evidence to show that sulfasalazine—another common DMARD—provides any benefit in reducing joint pain or slowing the progression of the disease in those with AS
OBJECTIVE To evaluate the efficacy and toxicity of sulfasalazine (SSZ) for the treatment of ankylosing spondylitis (AS)